Tadashi Watabe1,2, Motohide Uemura3, Fumihiko Soeda4, Sadahiro Naka5, Takeshi Ujike3, Koji Hatano3, Hidetaka Sasaki5, Takashi Kamiya5, Eku Shimosegawa6,7, Hiroki Kato4,6, Jens Cardinale8, Ukihide Tateishi9, Norio Nonomura3, Frederik L Giesel6,8,10. 1. Department of Nuclear Medicine and Tracer Kinetics, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan. watabe@tracer.med.osaka-u.ac.jp. 2. Institute for Radiation Sciences, Osaka University, Osaka, Japan. watabe@tracer.med.osaka-u.ac.jp. 3. Department of Urology, Graduate School of Medicine, Osaka University, Osaka, Japan. 4. Department of Nuclear Medicine and Tracer Kinetics, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan. 5. Department of Radiology, Osaka University Hospital, Osaka, Japan. 6. Institute for Radiation Sciences, Osaka University, Osaka, Japan. 7. Department of Molecular Imaging in Medicine, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan. 8. Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany. 9. Department of Diagnostic Radiology, Medical Hospital, Tokyo Medical and Dental University, Tokyo, Japan. 10. Department of Nuclear Medicine, University Hospital Düsseldorf, Düsseldorf, Germany.
Abstract
OBJECTIVE: 18F-labeled prostate-specific membrane antigen (PSMA) ligand, [18F]PSMA-1007, has the benefit of a higher synthetic yield and minimal excretion in the urine. High detection efficacy was reported in biochemical recurrence (BCR) of prostate cancer after radical prostatectomy. Thus, we evaluated the preliminary diagnostic utility of [18F]PSMA-1007 PET in patients with prostate cancer, focusing on the BCR which is not detected on conventional imaging. METHODS: We enrolled a total of 28 patients (age 51-79 years) with BCR of prostate cancer. BCR was defined as a continuous increase in PSA after radical prostatectomy or radiation therapy without any apparent recurrent lesions on conventional diagnostic imaging (CT and bone scintigraphy). PSMA-PET scanning was performed approximately 60 min after intravenous injection of [18F]PSMA-1007 (259 ± 37 MBq). PSMA-PET images were evaluated for lesion detection as well as its relation to PSA values and location. RESULTS: Abnormal uptake, which was suspected to be recurrence or metastasis, was detected in 92.9% (26/28) of patients with BCR. The SUVmax was 8.4 ± 6.4 in local recurrence, 11.5 ± 11.8 in pelvic lymph nodes (LN), and 4.1 ± 1.6 in bone metastasis. The detection rates were 66.7% in the PSA group-1 (0.1-0.5 ng/mL), 85.7% in the PSA group-2 (0.5-1.0 ng/mL), and 100% in the PSA group-3 (above 1.0 ng/mL). Among the PET-positive BCR patients (n = 26), local recurrence was detected in 57.7% (15/26), pelvic LN in 42.3% (11/26), and bone metastasis in 15.4% (4/26). In 53% (8/15) of BCR patients who were suspected of local recurrence, focal uptake was detected adjacent to the bladder on [18F]PSMA-1007 PET. This suggested the significant advantage of having minimal physiological urine excretion. CONCLUSIONS: [18F]PSMA-1007 PET showed a high detection rate in recurrent and metastatic lesions. In patients with BCR, its high detection led to suitable treatment strategies, such as salvage radiation therapy or surgical removal of recurrent lymph nodes. TRIAL REGISTRATION: (UMIN Clinical Trials Registry) UMIN000037697.
OBJECTIVE: 18F-labeled prostate-specific membrane antigen (PSMA) ligand, [18F]PSMA-1007, has the benefit of a higher synthetic yield and minimal excretion in the urine. High detection efficacy was reported in biochemical recurrence (BCR) of prostate cancer after radical prostatectomy. Thus, we evaluated the preliminary diagnostic utility of [18F]PSMA-1007 PET in patients with prostate cancer, focusing on the BCR which is not detected on conventional imaging. METHODS: We enrolled a total of 28 patients (age 51-79 years) with BCR of prostate cancer. BCR was defined as a continuous increase in PSA after radical prostatectomy or radiation therapy without any apparent recurrent lesions on conventional diagnostic imaging (CT and bone scintigraphy). PSMA-PET scanning was performed approximately 60 min after intravenous injection of [18F]PSMA-1007 (259 ± 37 MBq). PSMA-PET images were evaluated for lesion detection as well as its relation to PSA values and location. RESULTS: Abnormal uptake, which was suspected to be recurrence or metastasis, was detected in 92.9% (26/28) of patients with BCR. The SUVmax was 8.4 ± 6.4 in local recurrence, 11.5 ± 11.8 in pelvic lymph nodes (LN), and 4.1 ± 1.6 in bone metastasis. The detection rates were 66.7% in the PSA group-1 (0.1-0.5 ng/mL), 85.7% in the PSA group-2 (0.5-1.0 ng/mL), and 100% in the PSA group-3 (above 1.0 ng/mL). Among the PET-positive BCR patients (n = 26), local recurrence was detected in 57.7% (15/26), pelvic LN in 42.3% (11/26), and bone metastasis in 15.4% (4/26). In 53% (8/15) of BCR patients who were suspected of local recurrence, focal uptake was detected adjacent to the bladder on [18F]PSMA-1007 PET. This suggested the significant advantage of having minimal physiological urine excretion. CONCLUSIONS: [18F]PSMA-1007 PET showed a high detection rate in recurrent and metastatic lesions. In patients with BCR, its high detection led to suitable treatment strategies, such as salvage radiation therapy or surgical removal of recurrent lymph nodes. TRIAL REGISTRATION: (UMIN Clinical Trials Registry) UMIN000037697.
Entities:
Keywords:
Biochemical recurrence; Diagnosis; PET; PSMA; Prostate cancer
Authors: Louise Emmett; Charlotte Yin; Megan Crumbaker; George Hruby; Andrew Kneebone; Richard Epstein; Quoc Nguyen; Adam Hickey; Noah Ihsheish; Gordon O'Neill; Lisa Horvath; Venu Chalasani; Phillip Stricker; Anthony M Joshua Journal: J Nucl Med Date: 2018-12-14 Impact factor: 10.057
Authors: Jens Cardinale; Martin Schäfer; Martina Benešová; Ulrike Bauder-Wüst; Karin Leotta; Matthias Eder; Oliver C Neels; Uwe Haberkorn; Frederik L Giesel; Klaus Kopka Journal: J Nucl Med Date: 2016-10-27 Impact factor: 10.057
Authors: Julie L Kasperzyk; Stephen P Finn; Richard Flavin; Michelangelo Fiorentino; Rosina Lis; Whitney K Hendrickson; Steven K Clinton; Howard D Sesso; Edward L Giovannucci; Meir J Stampfer; Massimo Loda; Lorelei A Mucci Journal: Cancer Epidemiol Biomarkers Prev Date: 2013-10-15 Impact factor: 4.254
Authors: Stefan A Koerber; Leon Will; Clemens Kratochwil; Matthias F Haefner; Henrik Rathke; Christophe Kremer; Jonas Merkle; Klaus Herfarth; Klaus Kopka; Peter L Choyke; Tim Holland-Letz; Uwe Haberkorn; Juergen Debus; Frederik L Giesel Journal: J Nucl Med Date: 2018-07-05 Impact factor: 10.057
Authors: Isabel Rauscher; Markus Krönke; Michael König; Andrei Gafita; Tobias Maurer; Thomas Horn; Kilian Schiller; Wolfgang Weber; Matthias Eiber Journal: J Nucl Med Date: 2019-06-28 Impact factor: 11.082
Authors: Frederik L Giesel; B Hadaschik; J Cardinale; J Radtke; M Vinsensia; W Lehnert; C Kesch; Y Tolstov; S Singer; N Grabe; S Duensing; M Schäfer; O C Neels; W Mier; U Haberkorn; K Kopka; C Kratochwil Journal: Eur J Nucl Med Mol Imaging Date: 2016-11-26 Impact factor: 9.236
Authors: Frederik L Giesel; Karina Knorr; Fabian Spohn; Leon Will; Tobias Maurer; Paul Flechsig; Oliver Neels; Kilian Schiller; Horacio Amaral; Wolfgang A Weber; Uwe Haberkorn; Markus Schwaiger; Clemens Kratochwil; Peter Choyke; Vasko Kramer; Klaus Kopka; Matthias Eiber Journal: J Nucl Med Date: 2018-07-24 Impact factor: 10.057
Authors: Katharina Sprute; Vasko Kramer; Stefan A Koerber; Manuel Meneses; Rene Fernandez; Cristian Soza-Ried; Mathias Eiber; Wolfgang A Weber; Isabel Rauscher; Kambiz Rahbar; Michael Schaefers; Tadashi Watabe; Motohide Uemura; Sadahiro Naka; Norio Nonomura; Jun Hatazawa; Constantin Schwab; Viktoria Schütz; Markus Hohenfellner; Tim Holland-Letz; Juergen Debus; Clemens Kratochwil; Horacio Amaral; Pete L Choyke; Uwe Haberkorn; Camilo Sandoval; Frederik L Giesel Journal: J Nucl Med Date: 2020-08-17 Impact factor: 10.057
Authors: Esther Mena; Steven P Rowe; Joanna H Shih; Liza Lindenberg; Baris Turkbey; Aloyse Fourquet; Frank I Lin; Stephen Adler; Philip Eclarinal; Yolanda L McKinney; Deborah E Citrin; William Dahut; Bradford J Wood; Richard Chang; Elliot Levy; Maria Merino; Michael A Gorin; Martin G Pomper; Peter A Pinto; Janet F Eary; Peter L Choyke; Kenneth J Pienta Journal: J Nucl Med Date: 2021-12-16 Impact factor: 11.082
Authors: Janna Morawitz; Julian Kirchner; Johannes Hertelendy; Christina Loberg; Lars Schimmöller; Mardjan Dabir; Lena Häberle; Eduards Mamlins; Christina Antke; Christian Arsov; Gerald Antoch; Lino M Sawicki Journal: EJNMMI Res Date: 2022-03-04 Impact factor: 3.138
Authors: Youssra Allach; Amina Banda; Willemijn van Gemert; Michel de Groot; Yvonne Derks; Melline Schilham; Alexander Hoepping; Lars Perk; Martin Gotthardt; Marcel Janssen; James Nagarajah; Bastiaan M Privé Journal: Cancers (Basel) Date: 2022-04-21 Impact factor: 6.639
Authors: Clemens Mingels; Karl Peter Bohn; Axel Rominger; Ali Afshar-Oromieh; Ian Alberts Journal: Eur J Nucl Med Mol Imaging Date: 2022-01-24 Impact factor: 10.057